Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016, Elsevier. This is an author produced version of a paper published in The Lancet Haematology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 1 December 2016
  • Accepted: 27 September 2016
  • Published (online): 12 November 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 21 Dec 2016 10:56
Last Modified: 18 Jul 2017 03:44
Published Version: http://doi.org/10.1016/S2352-3026(16)30165-X
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S2352-3026(16)30165-X

Share / Export

Statistics